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Abstract
Background: Denosumab, an anti-resorptive agent, IgG2 monoclonal antibody for human Receptor activator of 
nuclear factor-kappa B ligand (RANKL), has been related to the occurrence of osteonecrosis of the jaws. Thus, 
the aim of this study was to review the literature from clinical case reports, regarding the type of patient and the 
therapeutic approach used for osteonecrosis of the jaws induced by chronic use of Denosumab.
Material and Methods: For this, a literature review was performed on PubMed, Medline and Cochrane databas-
es, using the keywords “Denosumab” “anti-RANK ligand” and “Osteonecrosis of jaw”. To be included, articles 
should be a report or a serie of clinical cases, describing patients aged 18 years or over who used denosumab 
therapy and have received any therapy for ONJ. 
Results: Thirteen complete articles were selected for this review, totaling 17 clinical cases. The majority of ONJ 
cases, patients receiving Denosumab as treatment for osteoporosis and prostate cancer therapy. In most cases, 
patients affected by ONJ were women aged 60 or over and posterior mandible area was the main site of involve-
ment. Diabetes pre-treatment with bisphosphonates and exodontia were the most often risk factors related to the 
occurrence of this condition. Systemic and local antibiotic therapy with or without surgical debridement was the 
most used treatment for ONJ resolution. 
Conclusions: It is concluded that the highest number of ONJ cases caused by the use of anti-RANKL agents oc-
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curred in female patients, aged 60 years or older, under treatment for osteoporosis and cancer metastasis, and the 
most affected region was the mandible posterior.
Key words: Denosumab, osteonecrosis, adverse effects, osteoporosis, antineoplastic protocols.
Introduction
Denosumab is an IgG2 monoclonal antibody with high 
affinity and specificity for human Receptor activator 
of nuclear factor-kappa B ligand (RANKL). It acts as 
antiresorptive agent, inhibiting osteolysis and block-
ing interaction between RANKL and RANK (Receptor 
Activator of Nuclear Factor ᴋ B), preventing osteoclast 
differentiation and activation (1). This drug has a difer-
ent mechanism of action from bisphosphonates, since 
it acts on osteoclast precursors, preventing their for-
mation, differentiation and function via inhibition of 
RANKL action. 
In randomized and double-blind studies, Denosumab 
has proven benefits over bisphosphonates, for providing 
greater effectiveness and lower acute adverse reactions 
such as pyrexia and arthralgia, and chronic, including 
renal toxicity (2). Therefore, Denosumab is recently be-
ing used for postmenopausal osteoporosis and preven-
tion of bone metastases.
Although Denosumab presents fewer systemic adverse 
effects than bisphosphonates and acts by different mech-
anism of action, evidences indicate that Denosumab is 
also associated with Osteonecrosis of the Jaws (ONJ) 
(3). The ONJ is defined as the exposure of necrotic bone 
in the maxillofacial region for more than eight weeks 
in patients who a history of exposure to antiresorptive 
or antiangiogenic agentes and have not been undergone 
head and neck radiotherapy (4). The fact of the ONJ 
being associated with both most used antiresorptives 
agents, strongly suggests that the removal of osteoclasts 
is critical for the pathophysiology of ONJ. It should be 
noticed that less potent drugs, such as estrogen and cal-
citonin, are not associated with this condition, which 
indicates that the resorption inhibition level affect the 
development of ONJ (5).
The ONJ is a multifactorial disease, of which occur-
rence is predisposed by some factors. It includes local 
factors such as tooth extraction, dent alveolar surgery, 
periodontal disease, trauma from ill fitting dentures 
(6) and systemical factors such as malignant diseases 
(breast, lung and prostate, multiple myeloma), chemo-
therapy, chronic steroid therapy, smoking, diabetes and 
anaemia (7).
According prospective longitudinal studies phase III, 
such as Henry et al. (3), there was no difference between 
the incidence of ONJ events found in patients treated 
for bone metastases with zoledronic acid 4 mg (1.3%) 
or denosumab 120 mg (1.1%). The same was seen by 
Stopeck et al. (2), in another phase III study, which the 
incidence of ONJ in patients with breast cancer treated 
with zoledronic acid (1.4%) was similar to those treated 
with denosumab (2.0%). 
Based on the prospects for therapeutic use in large scale of 
Denosumab and its possible serious adverse effect on the 
maxillary bones, the aim of this study was to review the 
literature from clinical case reports, regarding the type of 
patient and the therapeutic approach used for osteonecrosis 
of the jaws induced by Denosumab chronic use.
Material and Methods
Literature data were carried out on PubMed, Medline 
and Cochrane databases from January 2010 to May 
2015, by using the keywords “Denosumab” or “anti-
RANK ligand” AND “Osteonecrosis of jaw”, in both 
English and Portuguese, together. It was not set any 
deadline for selection of papers.
Initially, a total of 216 studies were selected based on 
their titles and abstracts. Subsequently, full-text docu-
ments were obtained and a new selection was performed 
according to the following criteria:
• A case report or a series of clinical cases;
• Patients aged 18 years or over; 
• Patients who used denosumab therapy for prevention 
of bone metastasis and / or treatment of osteoporosis 
and giant cell tumours;
• Patients who have received any therapy for ONJ.
Only studies in Portuguese, English and Spanish were 
selected. Clinical trials that compared the effectiveness 
of Denosumab with other drugs, phase II or III stud-
ies, literature reviews, meta-analyses, letters to the edi-
tor that does not constitute clinical cases and historical 
comments were excluded from the study.
Based on the established criteria, 22 articles were se-
lected. These were submitted to a new selection. It was 
excluded a total of 9 articles: 3 repeated studies, 2 letters 
to the editor, 2 literature review articles and 2 compara-
tive studies of Denosumab and bisphosphonates, which 
do not comprise clinical case reports.
An independent review performed the selection. Dis-
crepancies about inclusion or exclusion of studies were 
solved by extensive discussion between the reviewer 
and one contributor. 
The parameters analysed were: Type of disease treated 
with anti-RANKL therapy, the characteristics of De-
nosumab therapy, patient age and sex, site affected by 
ONJ, local and systemic risk factors, treatment and con-
clusion of the case report.
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Results
Thirteen complete case reports or case series articles 
were selected for this review. Some of them constitute a 
compilation of reports (8-10), totalling 17 clinical cases 
(Table 1). 
The majority of ONJ cases were reported in patients 
receiving Denosumab as treatment for osteoporosis or 
osteopenia (47.0%; 8), followed by therapy for pros-
tate cancer (35.3%; 6), giant cell tumour (11.8% 2) and 
breast carcinoma (5.9%; 1). The therapeutic regimen 
varied according to aetiology of the disorder treated. In 
all patients, the drug was administered subcutaneously 
and doses ranged from 60 to 120 mg of denosumab. Five 
patients treated for prostate cancer (83.3%) received 120 
mg of denosumab every four weeks, for osteoporosis, 
in general, patients received 60 mg of the drug every 
six months. Those with giant cell tumour were treated 
with either three consecutive weekly administrations of 
120 mg, continuing with an injection every month or 
one 120 mg dose of Denosumab every three months, 
followed by a short-term treatment interruption, then 
returning to 120 mg, but once a month. Only one patient 
treated for prostate cancer had a different therapy, re-
ceiving 60 mg of the drug every six months (Table 1).
Three patients, one treated for breast cancer (11) and 
two others for osteoporosis (12,13), who received a sin-
gle dose of 60 mg of Denosumab developed ONJ after 
tooth extraction in posterior mandible area (Table 1). 
In most cases (76.5%; 13), patients affected by ONJ 
were aged 60 or over; three patients were close to reach 
that age (58 and 55 years) and another report occurred 
in a 26-year-old patient (14) (Table 1).
With regard to sex, nine cases of ONJ were reported in 
women (53.0%) and eight in men (47.0%) (Table 1).
The majority (15; 88.2%) of cases of ONJ occurred in 
posterior mandible area. Two of these patients devel-
oped ONJ in posterior maxilla simultaneously (10,15), 
while two others (11.8%) exhibited the lesion only in 
posterior maxilla region (9,10) (Table 1).
The systemic factors associated to the development of 
ONJ most present were: diabetes, which was reported 
in the two cases, as well as the treatment with bisphos-
phonates in seven patients (41.2%). Moreover, an arti-
cle cited existence of anaemia, while others mentioned 
chronic corticosteroid therapy and smoking. Although 
hypertension is not directly related to the occurrence of 
ONJ, it was cited in five (29.4%) reports, while obesity 
affected two of them (11.8%). Early extraction into the 
ONJ site was carried out in seven cases (41.2%), acting 
as a local traumatic factor in predisposing development 
of the disease (Table 1). 
Systemic and local antibiotic therapy (6; 35.3%) was the 
most used treatment for ONJ resolution (amoxicillin with 
or without clavulanic acid associated with mouthwashes 
with 0.12% chlorhexidine solution). However, clindamy-
cin (1, 5.9%) or penicillin intravenously, especially in 
patients with trismus, associated with metronidazole (1, 
5.9%) were also used. In many cases (7; 41.2%), antibi-
otic therapy was combined to surgical debridement of 
necrotic bone exposed. The use of propoxyphene and 
acetaminophen, non-steroidal anti-inflammatory drugs 
(NSAIDs), for pain control has been considered in three 
cases (17.7%). Furthermore, the use of bone anabolic 
agent (teriparatide) (13) or bone resection fluorescence-
guided was performed in one case (5.9%) (8), consist-
ing in other therapeutical options. A case report did not 
mention the treatment (Table 2 and 2 Continue).
After initial therapy, two articles mentioned the need for 
surgical intervention and three others reported the ap-
pearance of abscesses (16-18), two of these were located 
in submental region (16,17) (Table 2 and 2 Continue).
Discussion
The ONJ is a condition closely associated to BPs and 
its pathogenesis has not been well understood yet (5). 
However, it is known that this disorder is strongly asso-
ciated with reduced bone healing caused by antiresorp-
tive drugs. Bone resorption is essential for subsequent 
neoformation step, which leads to remodelling of this 
tissue (5). In this literature review, which includes clini-
cal case reports of ONJ patients on therapy with Deno-
sumab published between 2011 and 2014, this relation-
ship was confirmed.
Denosumab is an effective agent in reducing bone loss 
associated to menopause, markers of bone turnover, 
reducing new vertebral, hip and nonvertebral fractures 
by 68%, 40%, and 20%, respectively, besides increas-
ing bone mineral density (19). In the present study, most 
of the clinical cases analysed consisted of Denosumab 
treatment for osteoporosis and a case described using of 
this antiresorptive agent in the treatment for osteopenia 
(20). This drug can still be used effectively in bone me-
tastases therapy, which has great importance, since De-
nosumab has proved to be very effective in minimizing 
bone loss associated with breast and prostate cancers (1) 
and giant cell tumour (21), representing together 53% of 
cases included in this review.
It is known that according to the type of pathology, 
there is a particular therapeutic regimen for Denosumab 
use. For treatment of metastatic bone disease is recom-
mended 120 mg of Denosumab, administered subcuta-
neously, once every month (2,3), for osteoporosis 60 mg 
subcutaneously every 6 months (19) and for giant cell 
tumour treatment, it is required 120 mg every 4 weeks 
(21). Even though therapeutic regimens are well estab-
lished, there are cases of patients being treated by fol-
lowing different protocols. This variation may be related 
to different centers where the treatment is performed. 
Furthermore, the use of Denosumab is still being re-
searched and, as a consequence, many of the patients 
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Study Disease type Therapeutic regimen of Denosumab Age Sex ONJ site 
Risk factors associated with 
ONJ 
Taylor, 
Middlefell, 
Mizen, 2010 (25) 
Metastatic 
prostatic 
adenocarcinoma 
120 mg, subcutaneous, every 
4 weeks 60 years old Male 
Posterior 
mandible - Corticosteroid therapy 
Aghaloo, 
Felsenfeld, 
Tetradis, 2010 
(16) 
Sacral giant cell 
tumor 
120 mg, subcutaneous, once a 
week for 3 consecutive 
weeks. After a gap of 2 weeks 
, patient received a single 
dose of 120 mg every 4 
weeks. 
65 years old Female Posterior mandible 
- Diabetes mellitus 
- Morbid obesity 
- Previous treatment with 
alendronate (4 months) 
Diz et al., 2012 
(17) 
Prostatic 
adenocarcinoma 
120 mg, subcutaneous, every 
4 weeks. 73 years old Male 
Posterior 
mandible -Dental extraction  
Malan et al., 
2012 (15) 
Prostatic 
adenocarcinoma 
120 mg, subcutaneous, every 
4 weeks for 22 months (total 
of 26 injections). 
73 years old Male 
Posterior 
mandible and 
maxilla 
- Dental extraction  
- Obesity 
- A smoker for 40 years 
Rachner et al., 
2013 (12) Osteoporosis 
 
60 mg, subcutaneous. 
*The patient received only a 
single dose of Denosumab 
75 years old Female Posterior mandible 
- Previous treatment with 
alendronate (3 anos) 
- Corticosteroid therapy 
- Inflammatory bowel disease 
-Anaemia 
Pichardo et al., 
2013 (18) 
Prostate 
carcinoma 
60 mg, subcutaneous, once a 
6 months 74 years old Male 
Posterior 
mandible 
- Diabetes mellitus 
 
Aghaloo et al., 
2013 (14) Giant cell tumor 
120 mg, subcutaneous, once a 
3 months for 2 years. 
Therapy interrupted for about 
1 year and then returned to 
120 mg, subcutaneous, once a 
1 or 2 months. 
26 years old Male Posterior mandible Not reported 
Otto et al., 2013 
(8) 
Osteoporosis 60 mg, subcutaneous. 58 years old Female Posterior mandible 
-Previous treatment with 
alendronate. 
Osteoporosis 60 mg,subcutaneous, once a 6 months. 68 years old Female 
Posterior 
mandible 
- Dental extraction 
- Implant Placement 
Neuprez et al., 
2014 (13) Osteoporosis 
60 mg, subcutaneous, once a 
6 months. 
*The patient received only a 
single dose of Denosumab 
58 years old Male Posterior mandible - Dental extraction 
Sabater et al., 
2014 (20) Osteopenia 
60 mg, subcutaneous, once a 
6 months. 78 years old Female 
Posterior 
mandible 
- Dental extraction 
- Previous treatment with 
risedronate. 
Olate et al., 2014 
(11) 
Ductal carcinoma 
in breast. 
60 mg, subcutaneous 
*The patient received only a 
single dose of Denosumab 
55 years old Female Posterior mandible - Dental extraction 
O’Halloran 
 et al., 2014 (9) 
Metastatic 
Prostatic 
carcinoma 
120 mg, subcutaneous, 
monthly 60 years old Male 
Posterior 
mandible Not reported 
Prostate 
carcinoma 
120 mg subcutaneous, 
monthly 72 years old Male 
Posterior 
maxilla Not reported 
Tortajada, 
Gómez, Lozano, 
2014 (10) 
Osteoporosis and 
Rheumatoid 
Arthritis 
60 mg subcutaneously, every 
6 months 65 years old Female 
Mandible and 
maxilla 
- Previous treatment with 
Alendronate (5 years) 
Osteoporosis Not reported 69 years old Female Posterior mandible 
- Previous treatment with 
Alendronate (10 years) 
Osteoporosis Not reported 71 years old Female Posterior maxilla 
- Pretreatment with Alendronate 
and Risedronate (6 years) 
- Previous treatment with 
Zoledronic Acid (1 year) 
-Dental extraction 
!
Table 1. Profile of patients affected by ONJ induced by Denosumab.
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Table 2. Treatment and follow-up of ONJ induced by Denosumab cases.
Study ONJ treatment Follow up 
Taylor, Middlefell, 
Mizen, 2010 (25) 
- Systemic and local antibiotic therapy 
! Amoxicillin 500 mg orally (3 
times/day for 7 days) 
! Chlorhexidine gluconate 
(0.12%) for mouthwash. 
The mucosa healed and the patient had no symptoms after 
15 months 
Aghaloo, Felsenfeld, 
Tetradis, 2010 (16) 
-Systemic and local antibiotic therapy 
! Clindamycin 300 mg orally (4 
times / day) 
! Chlorhexidine 0.12% for 
mouthwash 
- Propoxyphene, 100 mg) for 4 to 6 h. 
After 8 weeks, the patient presented for follow-up with 
minimal change in the area of exposed bone but with 
slightly more erythematous gingival tissue surrounding the 
bony exposure.  
Two weeks later, the patient returned presenting moderate, 
erythematous, tender submental swelling causing her 
difficulty swallowing, without dental or other source of 
infection. It was  realized intravenous antibiotics and 
incision and drainage. While the patient was in surgery, a 
thorough oral examination revealed no direct etiology for 
the submental infection and no connection to the ONJ area. 
After the surgery, the infection subsided and the patient 
was discharged. 
Diz et al. 2012 (17) 
-Systemic and local antibiotic therapy 
! Amoxicillin 
! Chlorhexidine 
-Surgical debridement 
After 12 months, there was need for long-term antibiotic 
therapy and bone sequestration curettage. An submental 
abscess, requiring extraoral drainage, and increased 
osteolytic area adjacent to the 1st right lower molar, 
requiring surgical intervention for removal of the tooth and 
bone debridement. Until the last follow-up visit 
(June/2012), there was no evidence of recurrence. 
Malan et al. 2012 
(15) 
-Systemic and local antibiotic therapy 
! Amoxicillin/Clavulanate 875 
mg / 125 mg, v.o., (2 times / 
day for 14 days) 
! Chlorhexidine Gluconate 
0.12% to mouthwash 
- Surgical debridement 
- Hydrocodone/acetaminophen 5 mg / 
500 mg orally (every 6 hours as needed 
for pain). 
Over the next several months, the patient was maintaind on 
daily chlorhexidine mouth rinses. A panoramic radiograph 
obtained 5 months after cessation of denosumab and 3 
months after the initial debridement showed enhanced 
demarcation of a bony sequestrum in the right mandible 
and decreased height of alveolar bone at the right mandible. 
At 22 months after the extractions and 18 months after 
cessation of denosumab, the patient presented with a bone 
sequestrum that had spontaneously exfoliated. 
Rachner et al. 2013 
(12) 
- Antibiotic therapy 
- Surgical Debridement Not reported 
Pichardo et al. 2013 
(18) 
-Systemic antibiotic therapy 
! Penicillin and metronidazole 
intravenously for 5 days 
followed by an 8-week oral 
regimen 
- Surgical debridement 
Three weeks after surgery there were again two small areas 
of exposed bone in the 35 and 44 region, with a discharging 
extra-oral fistula.  Sixteen weeks after the first surgery the 
extra-oral fistula hadnot disappeared and bone could be 
probed through it with new abscess formation a second 
surgery was performed. During exploration from area 36 to 
46 a significant amount of subperiosteal bone formation 
was seen on both buccal and lingual surfaces. The affected 
bone was removed. 
Aghaloo et al. 2013 
(14) 
- Suspension of Denosumab for 2 
months 
-Systemic and local antibiotic therapy 
! Amoxicillin 500 mg orally 
(three times/day) 
! Chlorhexidine 0.12% for 
Mouthwash (2 times/day). 
- Surgical debridement with extraction 
of premolar and molar 
Not reported 
Otto et al. 2013 (8) 
- 100 mg  of doxycycline 2x / day 
preoperatively for 10 days. 
-Removal of necrotic bone through 
bone resection guided by fluorescence. 
The wound showed complete mucosal healing 6 weeks 
after surgery and the patient was asymptomatic. There were 
radiological signs of bone remodeling in the panoramic 
radiograph taken 1 year after surgery. 
Neuprez et al. 2014 
(13) 
- Surgical Debridement 
- Treatment with bone anabolic agent 
(teriparatide 20 g/day, subcutaneous) 
- Daily calcium supplement and vitamin 
D. 
Not reported 
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were accompanied by phase III studies. However, the 
accumulated dose and regimen Denosumab employed 
do not seem to influence ONJ development, since three 
cases (8-10) reported the occurrence of this event in 
patients who received only 60 mg of drug. It is known 
that the risk of ONJ is increased proportionally to the 
number of bisphosphonates doses, especially when it is 
combined with potent ones, such as pamidronate and 
zoledronic acid administered over time (22), differing 
from ONJ induced by Denosumab, which can occur 
with fewer infusions of the drug.
The patients who developed ONJ induced by Deno-
sumab are mostly over 60 years old, similar to those 
patients using BPs (6). Thus, the only young patient who 
developed this condition was being treated for giant cell 
tumour (14).
The occurrence of ONJ between the sexes was very 
similar (9 women; 8 men). However, cases in female pa-
tients were directly related to the larger number of case 
reports in patients with osteoporosis using Denosumab. 
In male patients, most of the studies demonstrated that 
Denosumab therapy was used for treatment of prostate 
carcinoma. Interestingly, there was a case in which a 
male patient was being treated for osteoporosis (13). 
The ONJ bisphosphonate-induced is also described in 
many studies since it affects more females, 67% (7). The 
preference of that condition in affecting women can be 
associated with the use of antiresorptive drugs, which is 
vastly used in treatments for typically female diseases 
such as osteoporosis and breast cancer. However, some 
studies point out that there are no gender differences 
in the development of this condition in patients using 
bisphosphonates (22).
Locally, some factors may influence the occurrence of 
ONJ. Among these factors, it is highlighted the pres-
ence of periodontitis and the need for extractions (6). 
Both therapeutic procedures are locally invasive and 
can be constituted as a source of bacterial infection and 
inflammation in the periodontal tissues and induce re-
modelling in the adjacent bone. In such cases, the pa-
tient that use antiresorptive agents not have their bone 
remodelled when submitted to dental intervention, ac-
cumulating inflammatory mediators and cells undergo-
ing apoptosis, resulting in an increased risk of develop-
ing osteonecrosis (5). 
Denosumab has an elimination half-life of approximate-
ly 32 days (1). It has been reported that the cessation of 
osteoclast activity occurs within 6 hours of subcutane-
ous denosumab injection and returns to normal func-
tion approximately 6 months thereafter (9). So, Otto et 
al. (8) recommended that any surgical intervention for 
ONJ be with held for at least 4 months after denosumab 
administration to avoid manifestation of ONJ. 
The mandible has a greater risk of developing ONJ, 
since the bone is denser and less vascularized, which 
further impairs the healing process (23). This risk is 
even greater in the posterior region, since this site is of-
ten subjected to masticatory stimulus, inducing alveolar 
bone to reshape continuously. Among the studies select-
ed for this review, the majority reported that ONJ was 
related to the use of systemic Denosumab in posterior 
mandible area, which confirms results found in the lit-
erature. Similarly, the majority of ONJ bisphosphonate-
induced also occurs in the mandibular bone, reaching 
70% of cases (22).
In addition to local risk factors, it is also known that 
systemic conditions have been associated with the de-
velopment of ONJ in patients using bisphosphonates. 
Diabetics have a less responsive immune system, with 
lower chemotaxis and activity of polymorph nuclear 
neutrophils, reduced peripheral vasculature and in-
creased production of inflammatory cytokines, leading 
Table 2 Continue. Treatment and follow-up of ONJ induced by Denosumab cases.
Sabater et al. 
2014 (20) 
-Systemic antibiotic therapy 
! Amoxicillin and Clavulanic Acid 
-Analgesics 
Not reported 
Olate et al. 
2014 (11) 
- Suspension of Denosumab 
-Local antibiotic therapy 
! Chlorhexidine 0.12% for mouthwash. 
Until November 2013, there were no changes in the clinical 
presentation of injury 
O’Halloran  
et al. 2014 (9) 
- Surgical Debridement After 4 months, the mucosa showed good healing and the patient remains asymptomatic to date. 
- Surgical Debridement 
The size of the oroantral fistula has reduced and conservative 
measures in this region have ensured that the soft tissues have 
remained healthy, but the defect was not fully-closed until 
publication of the article. 
Tortajada, 
Gómez, Lozano, 
2014 (10) 
- Surgical debridement 
-Local antibiotic therapy 
! Maintenance-treatment with oral 
antiseptics for one year 
After one year, it had been achieved healing bone injury. 
- -Systemic and local antibiotic therapy 
! Chlorhexidine After one year, boné sequestrum was spontaneously eliminated 
Not reported Not reported 
!
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the body to a hiperinflammatory state (24), which pre-
disposes a lower response to infections, especially in 
oral cavity. Furthermore, other factors are also related 
to ONJ development, such as chronic corticosteroid 
therapy, anaemia and smoking (6), which can induce 
changes in the immune response. Among the studies 
analysed in this review, some patients were diabetic or 
using corticosteroids, which could contribute to devel-
opment of ONJ (12,16,18,25).
Although some studies indicate a relation between obes-
ity and development of bisphosphonate-induced ONJ in 
cancer patients, it is postulated that this event can occur 
as a consequence of other factors related to cancer treat-
ment. Among these factors, it is highlighted the pro-
longed use of steroids, which predispose a substantial 
weight gain and consequent development of obesity. In 
addition, it is unclear whether obesity-associated ONJ is 
related to increase masticatory function, which can lead 
to micro-traumas in previously committed bone tissues. 
Additionally, obesity increases systemic inflammatory 
reactions (26), leading to local oxidative stress and it 
may contribute to the development of bone necrosis. 
In this literature review, two of the seventeen patients 
studied were obese (15,16), which does not denote a sig-
nificant casuist but becomes relevant as it highlights the 
importance of care to this group of patients.
Some studies revised affirmed that patients who de-
velop ONJ lesions were hypertensive (13,15,16,18). In 
case-control studies, hypertension was not correlated 
with increased risk of developing ONJ (7). However, 
some literature reviews atributtes hypertension as an 
endogenous risk factor for the ONJ development (27). 
Another case-report of this review showed that ONJ le-
sion appeared in a patient with hypothireoidism (16). A 
large retrospective study affirmed that this comorbidity 
may be a risk factor for developing ONJ (7). The authors 
associate hypothyroidism with delayed wound healing, 
which was seen in previous experimental studies. How-
ever, this is the only study to show this relationship. 
Therefore, a relationship with these comorbities is not 
well established in the literature and more studies be 
necessary to elucid these questions. 
The therapy for ONJ has not been well established yet. 
In general, the primary management is done in order to 
relieve pain, reduce lesion size and minimize inflam-
mation of hard and soft tissue, and/or infection. In most 
patients who develop ONJ by using bisphosphonates the 
initial approach is non-surgical and includes antibiotics 
(such as penicillin, clindamycin, cephalexin and amoxi-
cillin-clavulanate), antifungals (such as fluconazole and 
nystatin) and mouth rinses containing an antimicrobial 
solution (chlorhexidine digluconate) (7).
Seven publications (77.7%) opted for treatment with sys-
temic antibiotics associated with mouthwash with chlo-
rhexidine, whereas five of them (55.5%) associated this 
treatment with surgical/local debridement. Antibiotics 
were used in order to reduce the infection of exposed 
bone injury. Some studies show that antibiotic therapy 
alone is ineffective, making it necessary surgery to re-
move necrotic bone (16,18). Two (18.2%) clinical cases 
reported the need for surgical intervention, due to the 
emergence of a new area of necrotic bone (16,18). The 
surgical approach is based on the premise that bone ex-
posure, especially with sharp or jagged edges, and the 
formation of bone sequestrum increase the risk of new 
infections and inflammation, therefore should be elimi-
nated (28). 
In this respect, the bone resection guided by fluores-
cence can bring many benefits. This treatment involves 
drug administration (doxycycline) to the pre-surgical 
patient. This antibiotic, like other tetracyclines, has 
the ability to be deposited in living bone. Thus, when 
ingested, this drug reaches the vital bone through the 
blood stream and produces bright golden-yellow pig-
ment (29) visualized by fluorescence. In this display 
system (VELscope®), the blue light is emitted (400-460 
nm) and the viable bone embedded with doxycycline 
shows the golden-yellow fluorescence. Since the necrot-
ic bone, which received doxycycline deposits appears 
in blue colour. Thus, the bone resection is performed 
until all the necrotic bone is removed, remaining only 
fluorescent bone, which make the amount of bone to be 
debrided more precise (8). 
Another alternative treatment for ONJ showed in pre-
sented case reports reviwed in this study was Teri-
paratide, a recombinant human N-terminal fragment of 
parathyroid hormone, is a bone anabolic agent shown 
to increase bone mass and strength and reduces the 
incidence of vertebral and non-vertebral fractures in 
post-menopausal women with osteoporosis (30). In ONJ 
lesions, teriparatide administration active living bone 
turnover, causing progression of the separation of the 
sequestrum followed by normal mucosal coverage of 
the exposed bone (30) and can show a great effect when 
this kind of treatment is associated to surgical debrid-
ment. However, a case series with ONJ patients in stage 
3 lesions showed less favorable results regarding the use 
of this agent (30). A related disadvantage of teriparatide 
use is that this drug is contraindicated in patients with 
metastatic cancer because of their participation in pro-
moting metastasis (30). Despite the controversial results, 
the study Neuprez et al. (13) showed that medication, 
combined with the suspension of denosumab, may pro-
vide fast relief in denosumab-induced ONJ, Although 
further investigations are needed to better define the 
role of teriparatide in the treatment of ONJ. The authors 
affirmed that the increase in bone turnover that occurs 
when the drug is removed might have a synergistic ef-
fect to teriparatide to stimulate bone remodeling and 
help heal ONJ lesions (13). 
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In specific cases, it is recommended the use of other 
drugs, such as clindamycin, an amoxicillin substitute 
for penicillin-allergic patients (4). Besides, propoxy-
phene and acetaminophen, both non-steroidal anti-
inflammatory drugs (NSAIDs) used to control acute 
pain, which is a feature of ONJ, as well as intravenous 
administration of penicillin, particularly performed in 
patients with trismus, can be used. The suspension of 
Denosumab after the occurrence and treatment of ONJ 
has shown a preventive measure to avoid exacerba-
tion of initial condition and, in part, to obtain reversal 
of bone without remodelling activity (8) but not to re-
verse ONJ already installed. Unlike bisphosphonates, 
denosumab is not incorporated into the bone and there 
is no evidence of drug reciclyng. Therefore, the effects 
of denosumab on bone turnorver are rapidly reversible 
with the suspension, and the effect on bone remodeling 
seems to decrease within 6 months after cessation of 
treatment (8). In order to prevent ONJ, it is important 
to maintain a good oral hygiene associated with regular 
dental visits (6).
Conclusions
Based on these findings, it is concluded that the highest 
number of ONJ cases associated with the use of anti-
RANKL agents was related to treatment for osteoporo-
sis and metastasis of prostate cancer. This condition was 
more frequent in female patients aged 60 years or older, 
the most affected region was the mandible posterior 
area.  Neither the treatment regimen employed nor the 
duration of Denosumab therapy seems to influence the 
development of ONJ. However, local factors seem to be 
important for triggering this adverse effect. Although 
there is no consensus on the therapy used to treat ONJ 
yet, the use of mouthwash containing antiseptic solu-
tions and antibiotic therapy associated or not with curet-
tage of necrotic bone has been shown to be an effective 
treatment in most cases. Nevertheless, it is important 
further studies to understand the pathogenesis of De-
nosumab-related ONJ, since anti-RANKL agents have 
been widely used for therapeutic osteolytic diseases and 
it was not possible to estimate its prevalence yet.
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